Difficulty of adjuvant chemotherapy administration in patients with biliary tract cancer.
Adjuvant chemotherapy
Biliary tract cancer
Surgical procedure
Journal
Langenbeck's archives of surgery
ISSN: 1435-2451
Titre abrégé: Langenbecks Arch Surg
Pays: Germany
ID NLM: 9808285
Informations de publication
Date de publication:
24 Nov 2023
24 Nov 2023
Historique:
received:
12
07
2023
accepted:
29
10
2023
medline:
27
11
2023
pubmed:
24
11
2023
entrez:
24
11
2023
Statut:
epublish
Résumé
This study aimed to elucidate the difficulty of adjuvant chemotherapy administration in patients with biliary tract carcinoma (BTC). Clinical data of patients with BTC who underwent curative-intent surgery were retrospectively analyzed. The eligible patients were stratified into two groups according to the presence or absence of adjuvant chemotherapy administration (adjuvant and non-adjuvant groups), and the clinicopathological features were compared between the two groups. The ratios of adjuvant chemotherapy administration were investigated in each surgical procedure. Independent factors associated with no administration of adjuvant chemotherapy were analyzed using multivariate analyses. Among 168 eligible patients, 141 (83.9%) received adjuvant chemotherapy (adjuvant group), while 27 (16.1%) did not (non-adjuvant group). The most common surgical procedure was pancreaticoduodenectomy in the adjuvant group, and it was hepatectomy with extrahepatic bile duct resection (BDR) in the non-adjuvant group, respectively. The rate of no adjuvant chemotherapy was significantly higher in patients who underwent hepatectomy with BDR than in those who underwent other surgeries (p < 0.001). The most common cause of no adjuvant chemotherapy was bile leak in 12 patients, which occurred after hepatectomy with BDR in ten patients. Multivariate analyses revealed that hepatectomy with BDR and preoperative anemia were independently associated with no adjuvant chemotherapy (p < 0.001 and p < 0.001, respectively). Hepatectomy with BDR and subsequent refractory bile leak can be the obstacle to adjuvant chemotherapy administration in patients with BTC.
Identifiants
pubmed: 37999810
doi: 10.1007/s00423-023-03169-9
pii: 10.1007/s00423-023-03169-9
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
445Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jarnagin WR, Fong Y, DeMatteo RP, Gonen M, Burke EC, Bodniewicz BSJ et al (2001) Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma. Ann Surg 234:507–517
doi: 10.1097/00000658-200110000-00010
pubmed: 11573044
pmcid: 1422074
de Groen PC, Gores GJ, LaRusso NF, Gunderson LL, Nagorney DM (1999) Biliary tract cancers. N Engl J Med 341:1368–1378
doi: 10.1056/NEJM199910283411807
pubmed: 10536130
Rizvi S, Khan SA, Hallemeier CL, Kelley RK, Gores GJ (2018) Cholangiocarcinoma — evolving concepts and therapeutic strategies. Nat Rev Clin Oncol 15:95–111
doi: 10.1038/nrclinonc.2017.157
pubmed: 28994423
Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC (2002) Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 37:806–813
doi: 10.1016/S0168-8278(02)00297-0
pubmed: 12445422
Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A et al (2001) Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut 48:816–820
doi: 10.1136/gut.48.6.816
pubmed: 11358902
pmcid: 1728314
Murakami Y, Uemura K, Sudo T, Hashimoto Y, Kondo N, Nakagawa N et al (2013) Perineural invasion in extrahepatic cholangiocarcinoma: prognostic impact and treatment strategies. J Gastrointest Surg 17:1429–1439
doi: 10.1007/s11605-013-2251-0
pubmed: 23797881
Nagahashi M, Shirai Y, Wakai T, Sakata J, Ajioka Y, Nomura T et al (2010) Depth of invasion determines the postresectional prognosis for patients with T1 extrahepatic cholangiocarcinoma. Cancer 116:400–405
doi: 10.1002/cncr.24766
pubmed: 19950133
Blom D, Schwartz SI (2001) Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch Surg 136:209–215
doi: 10.1001/archsurg.136.2.209
pubmed: 11177143
Kamposioras K, Anthoney A, Fernández Moro C, Cairns A, Smith AM, Liaskos C (2014) Impact of intrapancreatic or extrapancreatic bile duct involvement on survival following pancreatoduodenectomy for common bile duct cancer. Br J Surg 101:89–99
doi: 10.1002/bjs.9367
pubmed: 24375301
Jang JY, Kim SW, Park DJ, Ahn YJ, Yoon YS, Choi MG et al (2005) Actual long-term outcome of extrahepatic bile duct cancer after surgical resection. Ann Surg 241:77–84
doi: 10.1097/01.sla.0000150166.94732.88
pubmed: 15621994
pmcid: 1356849
Sakamoto Y, Kosuge T, Shimada K, Sano T, Ojima H, Yamamoto J et al (2005) Prognostic factors of surgical resection in middle and distal bile duct cancer: ana nalysis of 55 patients concerning the significance of ductal and radial margins. Surgery 137:396–402
doi: 10.1016/j.surg.2004.10.008
pubmed: 15800484
Kobayashi A, Miwa S, Nakata T (2010) Disease recurrence patterns after R0 resection of hilar cholangiocarcinoma. Br J Surg. 97:56–64
doi: 10.1002/bjs.6788
pubmed: 19937985
Komaya K, Ebata T, Shirai K, Ohira S, Morofuji N, Akutagawa A et al (2017) Recurrence after resection with curative intent for distal cholangiocarcinoma. Br J Surg 104:426–433
doi: 10.1002/bjs.10452
pubmed: 28138968
Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP et al (2012) Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut 61:1657–1669
doi: 10.1136/gutjnl-2011-301748
pubmed: 22895392
Ebata T, Kosuge T, Hirano S, Unno M, Yamamoto M, Miyazaki M et al (2014) Proposal to modify the International Union against Cancer staging system for perihilar cholangiocarcinomas. Br J Surg 101:79–88
doi: 10.1002/bjs.9379
pubmed: 24375300
Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H (2009) Adjuvant gemcitabine plus S-1 chemotherapy improves survival after aggressive surgical resection for advanced biliary carcinoma. Ann Surg 250:950–956
doi: 10.1097/SLA.0b013e3181b0fc8b
pubmed: 19953713
Primrose JN, Fox RP, Palmer DH, Malik HZ, Prasad R, Mirza D et al (2019) Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomized, controlled, multicentre, phase 3 study. Lancet Oncol 20:663–673
doi: 10.1016/S1470-2045(18)30915-X
pubmed: 30922733
Kobayashi S, Nagano H, Tomokuni A, Gotoh K, Sakai D, Hatano E et al (2019) A prospective, randomized phase II study of adjuvant gemcitabine versus S-1 after major hepatectomy for biliary tract cancer (KHBO 1208). Ann Surg 270:230–237
doi: 10.1097/SLA.0000000000002865
pubmed: 30339627
Nakachi K, Ikeda M, Konishi M, Nomura S, Katayama H, Kataoka T et al (2023) Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet 401:195–203
doi: 10.1016/S0140-6736(22)02038-4
pubmed: 36681415
Sakamoto Y, Sano T, Shimada K, Kosuge T, Kimata Y, Sakuraba M et al (2006) Clinical significance of reconstruction of the right hepatic artery for biliary malignancy. Langenbeck’s Arch Surg 391:203–208
doi: 10.1007/s00423-006-0026-8
Nagino M, Nimura Y, Nishio H, Ebata T, Igami T, Matsushita M et al (2010) Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases. Ann Surg 252:115–123
doi: 10.1097/SLA.0b013e3181e463a7
pubmed: 20531001
Nagino M, Kamiya J, Arai T, Nishio H, Ebata T, Nimura Y (2006) “Anatomic” right hepatic trisectionectomy (extended right hepatectomy) with caudate lobectomy for hilar cholangiocarcinoma. Ann Surg 243:28–32
doi: 10.1097/01.sla.0000193604.72436.63
pubmed: 16371733
pmcid: 1449975
Takagi T, Yokoyama Y, Kokuryo T, Ebata T, Ando M, Nagino M (2017) A clear difference between the outcomes after a major hepatectomy with and without an extrahepatic bile duct resection. World J Surg 41:508–515
doi: 10.1007/s00268-016-3744-2
pubmed: 27718004
Terasaki F, Hirakawa S, Tachimori H, Sugiura T, Nanashima A, Komatsu S et al (2023) Morbidity after left trisectionectomy for hepato-biliary malignancies: an analysis of the National Clinical Database of Japan. J Hepatobiliary Pancreat Sci. https://doi.org/10.1002/jhbp.1358
Matsuda T, Umeda Y, Matsuda T, Endo Y, Sato D, Kojima T et al (2021) Preoperative prognostic nutritional index predicts postoperative infectious complications and oncological outcomes after hepatectomy in intrahepatic cholangiocarcinoma. BMC Can 21:708
doi: 10.1186/s12885-021-08424-0
pubmed: 34130648
pmcid: 8207701
Terasaki F, Sugiura T, Okamura Y, Ito T, Yamamoto Y, Ashida R et al (2021) Use of preoperative controlling nutritional status (CONUT) score as a better prognostic marker for distal cholangiocarcinoma after pancreatoduodenectomy. Surg Today 51:358–365
doi: 10.1007/s00595-020-02098-0
pubmed: 32761459